WTAP and metastatic melanoma: In anti-PD-1 immunotherapy cohort (GSE78220; Patients with metastatic melanoma treated with anti-PD-1 antibody immunotherapy), patients with a high expression of WTAP exhibited a survival benefit trend (Supplementary Figure S5F).